Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The Company's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).

Number of employees : 302 people.
Sales per Business
20192020Delta
Ribonucleic Acid Interference Technology Platform23.90100%164.31100% +587.36%
USD in Million
Sales per region
20192020Delta
United States23.90100%164.31100% +587.36%
USD in Million
Managers
Name Title Age Since
Douglas M. Fambrough, Dr. President, Chief Executive Officer & Director 51 2010
Douglas W. Pagßn Chief Financial Officer 48 2020
Bob D. Brown, Dr. Chief Scientific Officer 55 2019
Shreeram Aradhye, Dr. Chief Medical Officer & Executive Vice President 57 2020
James B. Weissman Chief Operating Officer & Executive Vice President 58 2019
Stephen J. Hoffman, Dr. Independent Director 67 2007
Martin I. Freed, Dr. Independent Director 59 2016
Adam M. Koppel, Dr. Independent Director 50 2017
J. Kevin Buchi Chairman 65 2019
Cynthia Smith Independent Director 51 2018
Members of the board
Name Title Age Since
J. Kevin Buchi Chairman 65 2019
Douglas M. Fambrough, Dr. President, Chief Executive Officer & Director 51 2010
Stephen J. Hoffman, Dr. Independent Director 67 2007
Martin I. Freed, Dr. Independent Director 59 2016
Adam M. Koppel, Dr. Independent Director 50 2017
Cynthia Smith Independent Director 51 2018
Marc D. Kozin Independent Director 58 2019
Patrick M. Gray Independent Director 71 2019
Stephen K. Doberstein, Dr. Independent Director 61 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 77,888,932 72,307,538 92.8% 0 0.0% 92.8%
Shareholders
NameEquities%
RTW Investments LP 7,582,396 9.75%
Eli Lilly and Company 5,414,185 6.97%
SSgA Funds Management, Inc. 3,886,181 5.00%
The Vanguard Group, Inc. 3,509,934 4.52%
Cormorant Asset Management LP 3,481,471 4.48%
Bain Capital Life Sciences LP 3,080,237 3.96%
Ecor1 Capital LLC 2,721,993 3.50%
T. Rowe Price Associates, Inc. (Investment Management) 2,682,596 3.45%
RA Capital Management LP 2,456,669 3.16%
Aquilo Capital Management LLC 2,456,595 3.16%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Dicerna Pharmaceuticals, Inc.